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Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with no
cure and limited treatment options. There is therefore an urgent need for effective therapeutic
interventions in this disease. This protocol outlines the strategy for a systematic review and
meta-analysis to identify, from in vivo animal and human induced pluripotent stem cell (hiPSC)
studies, potential therapeutic interventions for ALS. Our aim is to perform a comprehensive
review of the ALS literature to compile a list of (1) candidate interventions and (2) target path-
ways that may be of therapeutic benefit in patients with ALS.
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1 | INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating disease with
limited treatment options. The disease process is characterized by
the selective degeneration of motor neurons leading to muscle dener-
vation and subsequent atrophy. Patients progressively lose control
over their bodies resulting in death, usually from respiratory arrest,
usually within 3 to 5 years of a diagnosis. Current treatment strate-
gies rely on supportive management and symptom control. Only one
medication, riluzole, is licenced for clinical use. Riluzole is a sodium
channel blocker and may have other effects through inhibition of N-
Methyl-D-aspartic acid (NMDA) receptor signalling, glutamate release
and uptake, which might serve to dampen neuroexcitation.1 The
effects of this drug are only modest, improving survival by 2 to
3 months and perhaps delaying the onset of ventilator dependence
following respiratory failure. There have been no further successful
treatments since the identification of riluzole as a potential therapeu-
tic intervention in ALS, there is therefore an urgent need for effective
medications to treat this disease.
Systematic review and meta-analysis of ALS literature may help
us to identify potential therapeutic interventions from animal model
data with potential for clinical application. A recent systematic review
focused on the efficacy of stem cell therapy in ALS2 and previously,
analysis of the literature from the SOD1-G93A transgenic mouse
model of ALS3 identified commonly investigated pathways in the
pathophysiology of ALS. However, there has been no systematic
review and meta-analysis, to our knowledge, examining the ALS liter-
ature as a whole, encompassing efficacy of all therapeutic interven-
tions with the potential for clinical application. Furthermore, since the
review of the SOD1-G93A mouse model of ALS, the field has
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changed dramatically with a greater understanding of the genetic and
pathological mechanisms underpinning the disease and the establish-
ment of a variety of diverse animal models of the disease. We will
therefore examine the in vivo ALS literature with a focus on identify-
ing interventions and target pathways that may have a therapeutic
benefit in ALS.
2 | APPROACH
A systematic review will be performed assessing interventions
implemented in preclinical data from all in vivo models of ALS and
frontotemporal dementia (FTD) (given the clinical and genetic over-
lap between the diseases) including (1) mammalian models (mouse
and rat), (2) organisms with a central nervous system (Drosophila,
C. elegans and Zebrafish) and (3) multicellular eukaryotic models
such as yeast. The search strategy will also include data from
(4) human, induced, pluripotent stem cells (iPSCs) taken from
patients with ALS, due to their potential for a direct translational
application of the results. Individual meta-analyses will then be per-
formed for each of the interventions identified. Interventions will
also be grouped by their target pathway for further subgroup
analysis.
3 | OBJECTIVES
3.1 | PICOS framework
Population: in vivo studies in ALS and FTD.
Intervention: all therapeutic interventions.
Comparison: control or vehicle treatment group.
3.2 | Outcome measure
Primary outcome: mortality (spontaneous or euthanased); for hiPSCs,
cell death.
Secondary outcomes: (1) behavioural (locomotor, circadian
rhythm, memory, body weight), (2) biochemical (misfolded protein
load, markers of cell stress) and (3) histological measures (integrity of
motor neurons, axons, glia, astrocytes, neuromuscular junctions and
muscle).
Study design: all study types where outcome in animals or cells
exposed to the intervention is compared with that in animals or cells
not exposed to the intervention.
4 | METHODS
Sources: databases: (1) PubMed, (2) Medline and (3) EMBASE
NB: there will be no publication date restrictions and no language
restrictions.
Date of searches: April 8, 2016.
4.1 | Search method: Pubmed
4.1.1 | Search (1) animal model data
((“amyotrophic lateral sclerosis” or “motor neuron disease” or “fronto-
temporal dementia” or FTLD or FTD or MND or ALS) AND ((mouse
or mice or murine) or rat or (drosophila or “fruit fly”) or “c. elegans” or
“zebra fish” or yeast)) AND Animals[Mesh:noexp]
4.1.2 | Search (2) iPSC data
(((“amyotrophic lateral sclerosis” or “motor neuron disease” or “fronto-
temporal dementia” or FTLD or FTD or MND or ALS) AND (iPSCs OR
“stem cells”)) AND ( ( Animals[Mesh:noexp] OR Humans[Mesh] ) ))
4.2 | Search method: EMBASE
4.2.1 | Search (1) animal model data
((Amyotrophic lateral sclerosis or ALS or Motor neuron disease or
MND or Frontotemporal dementia or FTD or FTLD) and (Mouse or
murine or mice or rat or drosophila or fruit fly or c elegans or zebra
fish or yeast)).af. and animal.sh.
4.2.2 | Search (2) iPSC data
((Amyotrophic lateral sclerosis or ALS or Motor neuron disease or
MND or Frontotemporal dementia or FTD or FTLD) and (iPSCs or
stem cells)).af. and human.sh.
4.3 | Search method: Medline
4.3.1 | Search (1) animal model data
((Amyotrophic lateral sclerosis or ALS or Motor neuron disease or
MND or Frontotemporal dementia or FTD or FTLD) and (Mouse or
murine or mice or rat or drosophila or fruit fly or c elegans or zebra
fish or yeast)).af. and animal.hw.
4.3.2 | Search (2) iPSC data
((Amyotrophic lateral sclerosis or ALS or Motor neuron disease or
MND or Frontotemporal dementia or FTD or FTLD) and (iPSCs or
stem cells)).af.
4.4 | Screening
We will use the Systematic Review Facility online screening tool
(app.syrf.org.uk). We will screen the title and abstract of each paper
identified and for potentially relevant papers the full text will be
retrieved, imported to EndNote and duplicate records will be dis-
carded. Two independent reviewers will assess each paper (for
screening and data extraction) with regards to the inclusion and
exclusion criteria and a quality score and will extract data as
described below. If reviewer concordance is <0.66 a third reviewer
will assess the paper.
4.5 | Eligibility
4.5.1 | Inclusion criteria
• All therapeutic interventions where outcome is compared with
that in a control or placebo group in ALS or FTD disease models.
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• Types of model.
• Genetic (knock out/in) OR drug induced (not combinations).
• Yeast, Drosophila, Zebrafish, C. elegans, Mouse, Rat, human
induced pluripotent stem cells (hiPSCs).
4.5.2 | Exclusion criteria
• No control group.
• Clinical studies.
• Reviews.
• Letters and comments.
• Co-treatments.
• Combinations of genetic and pharmacological induction of
phenotype.
• Cancer cell lines and all non-human iPSC lines.
4.6 | Quality checklist
CAMARADES’ study quality checklist, adapted as follows:
Nine items will be considered, and the median number of check-
list items scored, and the interquartile range, will be calculated.
• Peer review publication.
• Statement of potential conflict of interests.
• Sample size calculation.
• Random allocation to group.
• Allocation concealment.
• Blinded assessment of outcome.
• Appropriate control group identified.
• Compliance with animal welfare regulations.
• Statement of temperature control.
Study characteristics to be extracted:
• Study ID: (1) author and (2) year
• Intervention: (1i) drug from list identified from clinical data (drop-
down menu) or (2) other (free text box)
• Type of model: (1) which animal, (2) genetic or pharmacological
induction, (3) which protein/mutation (3) gender (4) mated or non-
mated or N/A, (5) familial or sporadic disease.
• Type of therapy: (1) immune, (2) genetic, (3) pharmacological,
(4) environmental (e.g. diet/temperature), (5) cell.
• Target pathway: (1) Calcium homeostasis, (2) excitotoxicity, (3) pro-
tein turnover, (4) apoptosis, (5) regeneration (6) trophic factor sig-
nalling, (7) immunomodulation, (8) inflammation, (9) oxidative
stress, (10) anion channel abnormalities, (11) lipid metabolism,
(12) energy balance (including mitochondrial disruption and
(13) axon transport.
• Mode of intervention delivery: (oral, intrathecal, intracerebroven-
tricular, intraventricular, intraspinal, intraparenchymal dialysis cath-
eter, intracranial cell transplantation/injection, subcutaneous,
intravenous, intramuscular, intraperitoneal).
• Sample size.
• Duration of intervention (1) single or (2) multiple or (3) continuous.
• Natural death or euthanased or N/A.
• Outcome: (1) outcome measure (2) primary or secondary (3) value.
4.7 | Statistical analysis
An individual meta-analysis will be carried out for each intervention
identified and a subgroup analysis of interventions grouped by puta-
tive biological target will also be performed. Additional subgroup ana-
lyses will include (1) assessment of SOD1 G93A mouse model
control-group survival data for evidence of genetic drift with time
and (2) comparison of efficacy of treatments and targets separately in
sporadic and familial models of disease.
The outcome measures will be plotted for each of the studies iden-
tified and included on a forest plot. Given the variability of model organ-
isms included in the analysis, primary outcome data (survival summary
data) will be calculated as described previously4 and secondary outcome
measures will be recorded in standardised mean differences (SMD), to
allow meaningful comparisons between studies. SMD will be compared
using Hedges g statistic, to account for bias from small sample sizes,
using a random effects model. Survival summary measures and SMDs
will be reported as odds ratios with 95% confidence intervals. Hetero-
geneity will be assessed for all outcome measures using I2 values, and a
funnel plot and Egger’s regression test will be used to assess publication
bias. The summary data from each analysis will then be compared to the
other meta-analyses on a separate forest plot and a hierarchy of candi-
date interventions will be identified.
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